In-Depth Pharmaceutical Deal Trends & Recent Deal Activity 2010-2015 Including Acquisition of Allergen by Actavis/Asset Transactions Between Novartis and GlaxoSmithKline/Partnership between Pfizer and Merck

Dec 09, 2015, 22:10 ET from Research and Markets

DUBLIN, Dec. 9, 2015 /PRNewswire/ -- Research and Markets ( has announced the addition of the "Pharmaceutical Deal Trends (2010-2015) and In-Depth Analysis of Recent Deal Activity" report to their offering.

This report discusses deal-making trends for a range of deal types, such as Mergers & Acquisitions (M&A) and strategic alliances. It also examines preference by deal type, along with disclosed deal values from 2010 to July 2015, covering start-ups, mid-level players, and big players.

Pharmaceutical companies use deal activity to enhance their research activities, regulatory approach, geographic presence, commercialization, and sales. The increasing development of biologics, especially in oncology, has given a significant boost to activity in recent years. Analysis suggests that while the number of deals in 2015 (until July) was lower than the number of deals in 2014, deal value in 2015 has already exceeded that of 2014.

Looking at the entire period, although strategic deals were more numerous, M&A deals had the highest deal value. Partnerships were the most preferred type of deal activity, but saw the lowest deal value. North America led in terms of region, followed by Europe and Asia-Pacific. Key deals covered in this report include the acquisition of Allergen by Actavis, asset transactions between Novartis and GlaxoSmithKline, and the partnership between Pfizer and Merck.


- Which challenges in the pharmaceutical industry are encouraging deal activity?
- How important is deal activity to the market?

Overview of deal activity from 2010 to 2015:

- What are the trends for M&A and strategic deals, and what are the key differences between the sectors?
- What was the trend for regional involvement in each year?
- How do variations in terms of therapy area preference affect deal activity?

Key Topics Covered:

1. Executive summary

2. Introduction

3. Overview

4. Traditional Model vs. Evolving Model

5. Factors Promoting Deal Activity

6. One-Stop Solution to Current Pharmaceutical Challenges

7. Deal Types

8. Overview of Pharmaceutical Deals from 2010 to 2015

9. Number of Pharmaceutical Deals and Value by Year

10. Pharmaceutical Deals by Region

11. Pharmaceutical Deals by Therapy Area

12. Overall Deal Analysis for 2014 and 2015

13. Announced and Completed Deals

14. Number of Deals and Deal Value by Deal Type

15. Number of Deals and Deal Value by Quarter

16. Regions of Deal Occurrence

17. Therapy Areas Promoting Deal Activity

18. Key Players in Deal Activity by Number of Deals and Deal Value

19. Mergers and Acquisitions Deal Activity for 2014 and 2015

20. Mergers and Acquisitions by Type of Deal and Deal Value

21. Mergers and Acquisitions by Region

22. Mergers and Acquisitions by Therapy area

23. Key Players in Mergers and Acquisitions

24. Description of Key Deals by Value

25. Strategic Alliances Deal Activity for 2014 and 2015

26. Strategic Alliance Deals by Type of Deal and Deal Value

27. Strategic Alliance Deals by Aggregate Deal Value, Upfront Payment and Milestone Payment

28. Strategic Alliance Deals by Region

29. Strategic Alliance Deals by Therapy Area

30. Strategic Alliance Deals by Product Phase

31. Strategic Alliance Deals by Molecule Type

32. Strategic Alliance Deals by Route of Administration

33. Key Players in Strategic Alliances

34. Description of Key Deals by Value

35. Bibliography and Appendix

Companies Mentioned

- Actavis
- Allergen
- GlaxoSmithKline Pfizer
- Merck
- Novartis

For more information visit

Media Contact: Laura Wood , +353-1-481-1716,


SOURCE Research and Markets